Annalise.ai vs Lunit
Both are FDA cleared, AI centrality A detection vendors on chest X-ray, but their scopes barely overlap, so for most buyers the choice follows the clinical need. If you need comprehensive multi finding coverage including head CT and a defined Medicare reimbursement path, start with Annalise.ai, whose breadth and neuro coverage Lunit does not match. If your priority is cancer detection backed by the deepest, most independently validated evidence in imaging AI, start with Lunit, the only vendor here that has twice submitted to third party head to head benchmarking. Annalise reads up to 124 findings on chest X-ray and 130 on head CT. Lunit is cancer focused across chest X-ray and mammography, with more than 100 peer reviewed publications behind it.
- Comprehensive multi finding breadth including neuro: up to 124 findings on chest X-ray and 130 on head CT, where Lunit is confined to cancer detection on chest X-ray and mammography with no head CT coverage.
- A defined US reimbursement path: Medicare New Technology Add on Payment status, which changes the return calculation for a hospital buyer.
- Time critical triage strength: the highest number of cleared triage findings on chest X-ray plus the first Breakthrough Device Designation ever granted to a radiology triage device.
- The deepest and most independent evidence base of any imaging vendor in the index: more than 100 peer reviewed publications, and the only one here to submit to third party head to head benchmarking twice, in JAMA Oncology against two commercial mammography products and in a Radboud multi vendor lung nodule validation.
- Cancer depth across two modalities: chest X-ray for lung plus mammography and tomosynthesis for breast, with published work specifically on dense breast tissue performance, the best documented failure mode in mammography screening.
- A lower friction adoption path: algorithms embedded directly into scanner hardware through OEM relationships, so a buyer can acquire the AI as part of equipment already being purchased.
Side-by-Side
| Axis | A Annalise.ai |
L Lunit |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Both are FDA cleared, AI centrality A detection vendors deployed across more than 40 countries, and neither publishes a security attestation or data residency terms. Their scopes barely overlap beyond chest X-ray: Lunit is cancer focused with no neuro, musculoskeletal, or emergency coverage, while Annalise is comprehensive findings with no mammography, so for most buyers the choice follows the clinical need rather than a like for like comparison. Annalise's evidence leans on deployment scale rather than peer reviewed outcomes, and its headline 32 percent head CT accuracy improvement lacks published study detail. Both are headquartered outside the US, Lunit in Korea and Annalise as an Australian joint venture, so a US buyer should establish business associate terms. Lunit's own evidence frames AI plus one radiologist as a replacement for two reader double reading, so buyers in double reading programs should treat the staffing implication as the real decision.